Table 1

Sensitivity of ES/PNET cells to chemotherapeutic agents after combined simultaneous treatments

ES/PNET cells were treated with progressive doses of doxorubicin (DXR) or vincristine (VCR) either alone or associated with αIR3 MAb (1 μg/ml), control MOPC-21 MAb (1 μg/ml) or suramin (250 μg/ml for TC-71 and LAP-35 cells; 100 μg/ml for SK-N-MC). Results represent the mean ± SE of triplicate experiments.
Cell linesTreatmentIC50 valuesa (ng/ml)Fold-increase in DXR and VCR sensitivity
TC-71DXR7.9 ± 0.65
DXR+MOPC-21 MAb11.5 ± 0.45
DXR+αIR3 MAb0.094 ± 0.012b84
DXR+suramin0.721 ± 0.055b11
VCR0.673 ± 0.077
VCR+MOPC-21 MAb0.513 ± 0.053
VCR+αIR3 MAb0.097 ± 0.008c7
VCR+suramin0.101 ± 0.012c7
SK-N-MCDXR4.5 ± 0.5
DXR+αIR3 MAb0.26 ± 0.02b17
DXR+suramin0.93 ± 0.04c5
VCR0.133 ± 0.02
VCR+αIR3 MAb0.052 ± 0.01d3
VCR+suramin0.048 ± 0.005d3
LAP-35DXR3.55 ± 0.15
DXR+αIR3 MAb0.062 ± 0.01b57
DXR+suramin0.27 ± 0.002b13
VCR1.19 ± 0.21
VCR+αIR3 MAb0.009 ± 0.002c132
VCR+suramin0.27 ± 0.09d4
  • a Drug concentration resulting in 50% inhibition of cell growth.

  • b P < 0.001; Student’s t test.

  • c P < 0.01; Student’s t test.

  • d P < 0.05; Student’s t test.